Skip to main content

Meridian Simplifies Workflows for POC Molecular Tests with a New Lyo-Ready™ LAMP Mix

Written by Customer Service on . Posted in Public Companies.

CINCINNATI, April 28, 2021 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc., a leading global provider of diagnostic testing solutions and life science raw materials, announced today the launch of the Lyo-Ready™ DNA LAMP Mix, specifically designed for accelerating the development of ambient temperature-stable loop-mediated isothermal amplification (LAMP) assays. The Lyo-Ready™ DNA LAMP Mix is formulated for rapid, robust, and sensitive DNA amplification through nucleic acid strand displacement.

The COVID-19 pandemic has highlighted the benefit of point-of-care molecular diagnostic testing. LAMP assays are perfectly suited for point-of-care or portable testing because they are performed at one single temperature which reduces the cost and complexity of the device without the requirement of a thermocycler. Additionally, to further support point-of-care testing, molecular diagnostic tests are progressively moving towards formats that avoid cold storage requirements.

To facilitate development of such tests, Meridian designed the new Lyo-Ready™ DNA LAMP Mix as a glycerol-free, and uniquely high 4x concentration format mix, containing pre-optimized lyo-excipients. Once target-specific primers/probes are added, the mix is ready to be lyophilized, making it ideal for faster development of room temperature stable LAMP assays with superior amplification sensitivity and specificity.

Florent Chang-Pi-Hin, Ph.D., Sr. Director of Research & Development – Life Science, commented, “LAMP is increasingly used in molecular diagnostics as a field-friendly alternative to many other complex molecular methods. We are delighted to announce the release of our new Lyo-Ready™ LAMP Mix, which outperforms the competition with excellent sensitivity and specificity while also reducing overall assay development and manufacturing costs.”

Meridian is committed to providing innovative solutions to diagnostic manufacturers that simplify and accelerate the development of superior diagnostic assays. For more information about partnering with Meridian Bioscience, please visit https://meridianlifescience.com/lyophilization-ready-qpcr-rt-qpcr-mixes or contact Dr. Chang-Pi-Hin at florent.chang-pi-hin@meridianlifescience.com.

About Meridian Bioscience, Inc.
Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic products. We are dedicated to developing and delivering better solutions that give answers with speed, accuracy and simplicity that are redefining the possibilities of life from discovery to diagnosis. Through discovery and development, we provide critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, we provide diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing. We build relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world.

Meridian’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian’s website address is www.meridianbioscience.com.

Contact:
Charlie Wood
Vice President – Investor Relations
Meridian Bioscience, Inc.
Phone: +1 513.271.3700
Email: mbi@meridianbioscience.com

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.